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Objective 
Indoleamine 2,3 – dioxygenase (IDO) is 
an enzyme that aids in 
immunosuppression and tolerance.  
Previous studies have shown decreased 
IDO activity in pregnancies affected by 
preeclampsia, but the mechanism for 
this altered activity is unknown. Our 
study was designed to analyze the 
promoter region of IDO in preeclamptic 
and control women and identify the 
frequency of a VNTR genotype that has 
been shown to be significantly 
correlated with tryptophan levels in 
women; a surrogate marker for IDO 
activity.  
Methods 
We conducted a retrospective case-
control study examining preeclamptic 
women, including mild, severe, and 
superimposed preeclamptic women, and 
control women for a VNTR 
polymorphism.  Study participants were 
selected from the University of Iowa’s 
Maternal Fetal Tissue Bank.  The VNTR 
region was amplified from genomic 
DNA. Electrophoresis was used to 
determine whether each woman carried 
the V1/V1, V1/V2, or V2/V2 genotype. 
Genotypes from preeclampsia cases 
were compared to controls using a 
Fisher’s exact test.  
Results 
Thirty three preeclamptic women were 
analyzed for this study and compared to 
53 control women.  We found no 
statistically significant predominance of 
one genotype in the preeclamptic group 
compared to the control group.  (V1/V1 
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8/33 vs 8/53; P = 0.39, V1/V2 15/33 vs 
24/53; P = 1.0, V2/V2 10/33 vs 21/53; P 
= 0.49.) 
Conclusions 
Our study did not document a significant 
difference of the VNTR genotype in 
preeclamptic women when compared to 
control women.  
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